ProKidney Corp.
General ticker "PROK" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $533.7M (TTM average)
ProKidney Corp. follows the US Stock Market performance with the rate: 46.6%.
Estimated limits based on current volatility of 4.1%: low 2.29$, high 2.48$
Factors to consider:
- Total employees count: 204 (+25.2%) as of 2024
- Top business risk factors: Dependence on lead product, Regulatory and compliance, Transition to commercialization, Manufacturing risks, Profitability concerns
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.16$, 3.58$]
- 2025-12-31 to 2026-12-31 estimated range: [1.37$, 4.01$]
Financial Metrics affecting the PROK estimates:
- Positive: with PPE of -2.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -77.84 <= 0.33
- Positive: Investing cash flow per share per price, % of 12.58 > -0.66
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0.01 <= 0.01
Short-term PROK quotes
Long-term PROK plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.08MM |
| Operating Expenses | $153.01MM | $151.52MM | $183.75MM |
| Operating Income | $-153.01MM | $-151.52MM | $-183.68MM |
| Non-Operating Income | $5.77MM | $22.07MM | $19.74MM |
| Interest Expense | $0.21MM | $0.01MM | $0.01MM |
| R&D Expense | $82.07MM | $106.71MM | $127.67MM |
| Income(Loss) | $-147.24MM | $-129.45MM | $-163.93MM |
| Taxes | $0.90MM | $6.00MM | $-0.60MM |
| Profit(Loss)* | $-108.03MM | $-35.47MM | $-61.19MM |
| Stockholders Equity | $-1,096.62MM | $-1,103.40MM | $-994.95MM |
| Assets | $518.00MM | $420.55MM | $441.07MM |
| Operating Cash Flow | $-77.09MM | $-90.07MM | $-126.35MM |
| Capital expenditure | $1.85MM | $34.20MM | $29.51MM |
| Investing Cash Flow | $-1.74MM | $-329.98MM | $20.41MM |
| Financing Cash Flow | $548.52MM | $-9.55MM | $144.41MM |
| Earnings Per Share** | $-1.76 | $-0.57 | $-0.62 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.